TY - JOUR
T1 - Impairment in work and activities of daily life in patients with psoriasis
T2 - results of the prospective BioCAPTURE registry
AU - van Hal, Tamara W.
AU - van den Reek, Juul M.P.A.
AU - Wenink, Mark H.
AU - Otero, Marisol E.
AU - Ossenkoppele, Paul M.
AU - Njoo, Marcellus D.
AU - Oostveen, Annet
AU - Peters, Bas
AU - Tjioe, Milan
AU - Kop, Else N.
AU - Körver, John E.M.
AU - Dodemont, Sharon R.P.
AU - Kleinpenning, Marloes M.
AU - Berends, Maartje A.M.
AU - Veldkamp, Wendelien R.
AU - van Doorn, Martijn B.A.
AU - Mommers, Johannes M.
AU - Lindhout, Robert Jan
AU - Kuijpers, Astrid L.A.
AU - van Lümig, Paula P.
AU - de Jonge, C. (Els) J.
AU - Tupker, Ron A.
AU - Hendricksen, Judith
AU - Keijsers, Romy R.
AU - van den Hoogen, Frank H.J.
AU - Vriezekolk, Johanna E.
AU - de Jong, Elke M.G.J.
N1 - Publisher Copyright:
© 2024 Sint Maartenskliniek. Published with license by Taylor & Francis Group, LLC.
PY - 2024
Y1 - 2024
N2 - Background: Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this study aimed to assess these impairments in patients with psoriasis who started using biologicals/small molecule inhibitors. Methods: Using data from the prospective BioCAPTURE registry, we collected patient, disease, and treatment parameters, as well as work/ADL impairments at baseline, 6 and 12 months. Changes in impairment parameters and correlations between impairment and patient/disease characteristics were assessed using generalized estimating equations. Results: We included 194 patients in our analysis. After biological initiation, disease activity decreased significantly (PASI 11.2 at baseline versus 3.9 at 12 months, p < 0.001). Work-for-pay in this cohort was lower than in the Dutch general population (53% versus 67%, p = 0.01). In patients who had work-for-pay, presenteeism improved over time (5% at baseline versus 0% at 12 months, p = 0.04). Up to half of the patients reported impairments in ADL, which did not change over time. Associations between impairments and contextual factors varied, but all impairments were associated with worse mental/physical general functioning. Conclusion: Patients with psoriasis using biologicals are less likely to have work-for-pay. Treatment improves the work productivity of employed patients, but we were unable to detect changes in ADL performance.
AB - Background: Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this study aimed to assess these impairments in patients with psoriasis who started using biologicals/small molecule inhibitors. Methods: Using data from the prospective BioCAPTURE registry, we collected patient, disease, and treatment parameters, as well as work/ADL impairments at baseline, 6 and 12 months. Changes in impairment parameters and correlations between impairment and patient/disease characteristics were assessed using generalized estimating equations. Results: We included 194 patients in our analysis. After biological initiation, disease activity decreased significantly (PASI 11.2 at baseline versus 3.9 at 12 months, p < 0.001). Work-for-pay in this cohort was lower than in the Dutch general population (53% versus 67%, p = 0.01). In patients who had work-for-pay, presenteeism improved over time (5% at baseline versus 0% at 12 months, p = 0.04). Up to half of the patients reported impairments in ADL, which did not change over time. Associations between impairments and contextual factors varied, but all impairments were associated with worse mental/physical general functioning. Conclusion: Patients with psoriasis using biologicals are less likely to have work-for-pay. Treatment improves the work productivity of employed patients, but we were unable to detect changes in ADL performance.
UR - https://www.scopus.com/pages/publications/85183000325
U2 - 10.1080/09546634.2024.2304025
DO - 10.1080/09546634.2024.2304025
M3 - Article
C2 - 38263716
AN - SCOPUS:85183000325
SN - 0954-6634
VL - 35
JO - Journal of Dermatological Treatment
JF - Journal of Dermatological Treatment
IS - 1
M1 - 2304025
ER -